AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28738672 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐leg compression group
Number of subjects: 18
Study 28738672 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorts group
Number of subjects: 18
Study 28738672 — intervention group
Group type: EXPERIMENTAL
Intervention: Full‐leg compression garments
Number of subjects: 18
Study 28738672 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garments
Number of subjects: 18
Study 28738672 — intervention group
Group type: COMPARATOR
Intervention: Control (no compression garments)
Number of subjects: 18
Study 26792812 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg twice daily
Number of subjects: 505
Study 26792812 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 505
Study 26792812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study 24593917 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (annual treatment)
Number of subjects: 32
Study 24593917 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual treatment with oral azithromycin
Number of subjects: 32
Study 22822195 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar plexus block (LPB)
Number of subjects: 42
Study 22822195 — intervention group
Group type: COMPARATOR
Intervention: Control (no LPB)
Number of subjects: 42
Study 20699411 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 25 mg [(14)C]INCB018424
Number of subjects: 0
Study 20699411 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral doses of unlabeled INCB018424
Number of subjects: 0
Study 16988883 — intervention group
Group type: EXPERIMENTAL
Intervention: Education videotape
Number of subjects: 244
Study 16988883 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact videotape
Number of subjects: 244
Study 15773875 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulphate (40 mg daily)
Number of subjects: 10
Study 15773875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12114361 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (400 mg/d for 7 days)
Number of subjects: 0
Study 12114361 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (1,500 mg/d for 7 days)
Number of subjects: 0
Study 12114361 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (750 mg/d for 7 days)
Number of subjects: 0
Study 11149429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (2 microg/kg)
Number of subjects: 265
Study 11149429 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 265
Study 8795409 — intervention group
Group type: EXPERIMENTAL
Intervention: Isothermic irrigation fluid (Group 1)
Number of subjects: 59
Study 8795409 — intervention group
Group type: COMPARATOR
Intervention: Room temperature irrigation fluid (Group 2)
Number of subjects: 59
Study 8795409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 1459356 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human GIP (1 pmol/kg/min)
Number of subjects: 9
Study 1459356 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 [7-36 amide] (0.3 pmol/kg/min)
Number of subjects: 9
Study 1459356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GIP and GLP-1 [7-36 amide]
Number of subjects: 9
Study 1459356 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl with 1% albumin)
Number of subjects: 9
Study 4067972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of a large meal
Number of subjects: 8
Study 4067972 — intervention group
Group type: COMPARATOR
Intervention: Repeating the experiment without food or with salt content only
Number of subjects: 8
Study 31024969 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin (DNX)
Number of subjects: 45
Study 31024969 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin + Oseltamivir (DNX+OSV)
Number of subjects: 45
Study 31024969 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir (OSV)
Number of subjects: 45
Study 31024969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29656838 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO intervention (robotic seal)
Number of subjects: 138
Study 27998876 — intervention group
Group type: EXPERIMENTAL
Intervention: iPST
Number of subjects: 626
Study 27998876 — intervention group
Group type: EXPERIMENTAL
Intervention: Project: EVO
Number of subjects: 626
Study 27998876 — intervention group
Group type: COMPARATOR
Intervention: Health Tips
Number of subjects: 626
Study 23860287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed maximal and explosive strength training
Number of subjects: 34
Study 23860287 — intervention group
Group type: COMPARATOR
Intervention: Circuit training with body weight (Control)
Number of subjects: 34
Study 23860287 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 34
Study 23860287 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (experimental)
Number of subjects: 34
Study 23860287 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (experimental)
Number of subjects: 34
Study 22500712 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (1 bag/dose, two doses per day)
Number of subjects: 0
Study 22500712 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5mg/day)
Number of subjects: 0
Study 22500712 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 22500712 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 20801256 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral subtalar sling taping
Number of subjects: 16
Study 20801256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular repositioning taping
Number of subjects: 16
Study 20801256 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 16
Study 18981842 — intervention group
Group type: EXPERIMENTAL
Intervention: Watertight dural closure (Group A)
Number of subjects: 150
Study 18981842 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary watertight dural closure (Group B)
Number of subjects: 150
Study 18981842 — intervention group
Group type: COMPARATOR
Intervention: Adaptive dural closure (Group C)
Number of subjects: 150
Study 15911537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spine fusion
Number of subjects: 349
Study 15911537 — intervention group
Group type: COMPARATOR
Intervention: Intensive rehabilitation programme
Number of subjects: 349
Study 12885685 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) with Primary Care Management (PCM)
Number of subjects: 197
Study 12885685 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) with Cognitive Behavior Therapy (CBT)
Number of subjects: 197
Study 12885685 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with PCM
Number of subjects: 197
Study 12885685 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with CBT
Number of subjects: 197
Study 12885685 — intervention group
Group type: COMPARATOR
Intervention: Placebo with PCM
Number of subjects: 197
Study 12885685 — intervention group
Group type: COMPARATOR
Intervention: Placebo with CBT
Number of subjects: 197
Study 10369493 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan (four capsules twice daily for 28 days)
Number of subjects: 34
Study 10369493 — intervention group
Group type: COMPARATOR
Intervention: Placebo (indistinguishable capsules, four capsules twice daily for 28 days)
Number of subjects: 34
Study 7585493 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatalism
Number of subjects: 192
Study 7585493 — intervention group
Group type: EXPERIMENTAL
Intervention: FOBT participation
Number of subjects: 192
Study 2373656 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted group (16 parents)
Number of subjects: 32
Study 2373656 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 parents)
Number of subjects: 32
Study 6156364 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 150
Study 6156364 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 150
Study 6156364 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 31432556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg three times daily
Number of subjects: 135
Study 31432556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 30207136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) administered at a loading dose of 0.5 μg/kg, followed by an infusion of 0.4 μg/kg/h
Number of subjects: 68
Study 30207136 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 68
Study 27977825 — intervention group
Group type: EXPERIMENTAL
Intervention: LMCAF-M (laterally moved coronally advanced flap with microsurgical instruments)
Number of subjects: 50
Study 27977825 — intervention group
Group type: COMPARATOR
Intervention: LMCAF-C (conventional laterally moved coronally advanced flap)
Number of subjects: 50
Study 27977825 — intervention group
Group type: EXPERIMENTAL
Intervention: LMCAF-M
Number of subjects: 50
Study 27977825 — intervention group
Group type: COMPARATOR
Intervention: LMCAF-C
Number of subjects: 50
Study 24092869 — intervention group
Group type: EXPERIMENTAL
Intervention: Water method
Number of subjects: 72
Study 24092869 — intervention group
Group type: COMPARATOR
Intervention: Alcohol method
Number of subjects: 72
Study 23502220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 43
Study 23502220 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 43
Study 23502220 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 43
Study 21849374 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (n=15)
Number of subjects: 45
Study 21849374 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (n=15)
Number of subjects: 45
Study 19650754 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg
Number of subjects: 401
Study 19650754 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Number of subjects: 401
Study 19650754 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 10 mg
Number of subjects: 401
Study 19650754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 17452069 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock group (converted to ventricular fibrillation and were shocked)
Number of subjects: 738
Study 15690976 — intervention group
Group type: EXPERIMENTAL
Intervention: Human neuronal cells (hNT cells; LBS neurons) delivered in doses of 2 or 6 million cells in three or nine implants, or 5 or 10 million cells in 25 implants
Number of subjects: 26
Study 15690976 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic surgical technique for cell delivery
Number of subjects: 26
Study 15690976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell delivery cannula
Number of subjects: 26
Study 11198904 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing feedback about prior performance and confidence on specific test questions
Number of subjects: 0
Study 11198904 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 9453272 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic tension-type headache
Number of subjects: 80
Study 9453272 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 8091321 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 25, 50, 100, and 200 micrograms
Number of subjects: 12
Study 8091321 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 100, 500, 1000, and 1000 micrograms
Number of subjects: 12
Study 8091321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2663742 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin-based beverage (Mf) (20% w/v, 85% maltodextrin, 15% fructose)
Number of subjects: 13
Study 2663742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-maltodextrin beverage (FM) (50/50%)
Number of subjects: 13
Study 2663742 — intervention group
Group type: COMPARATOR
Intervention: Normal CHO-rich diet (N) (60 En%)
Number of subjects: 13
Study 2663742 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin-based beverage (Mf)
Number of subjects: 13
Study 2663742 — intervention group
Group type: COMPARATOR
Intervention: Normal CHO-rich diet (N)
Number of subjects: 13
Study 2663742 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-maltodextrin beverage (FM)
Number of subjects: 13
Study 787957 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80-320 mg daily, with increments up to 1200 mg as needed)
Number of subjects: 725
Study 787957 — intervention group
Group type: COMPARATOR
Intervention: Tranquilizers (control group)
Number of subjects: 725
Study 787957 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single-blind trials)
Number of subjects: 725
Study 31931026 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration (Icon, pre-product; DMG)
Number of subjects: 22
Study 31931026 — intervention group
Group type: COMPARATOR
Intervention: Mock treatment (control)
Number of subjects: 22
Study 28430638 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE+C+L
Number of subjects: 71
Study 28430638 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 71
Study 26293519 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine-dihydroartemisinin administered after a high-fat, high-calorie meal
Number of subjects: 0
Study 26293519 — intervention group
Group type: COMPARATOR
Intervention: Piperaquine-dihydroartemisinin administered after fasting
Number of subjects: 0
Study 23526799 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 2
Study 23526799 — intervention group
Group type: EXPERIMENTAL
Intervention: Nembutal
Number of subjects: 2
Study 21651652 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 42
Study 21651652 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 42
Study 19793357 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg
Number of subjects: 2366
Study 19793357 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 2366
Study 19793357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2366
Study 19793357 — intervention group
Group type: EXPERIMENTAL
Intervention: All alogliptin groups
Number of subjects: 2366
Study 19793357 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 2366
Study 19793357 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 2366
Study 17151088 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs
Number of subjects: 0
Study 17151088 — intervention group
Group type: COMPARATOR
Intervention: Standard antiepileptic drugs
Number of subjects: 0
Study 15128167 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) signal indices at T1-weighted images (T1WI)
Number of subjects: 138
Study 15128167 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI signal indices at S1 of T1WI
Number of subjects: 138
Study 15128167 — intervention group
Group type: COMPARATOR
Intervention: MRI signal indices
Number of subjects: 138
Study 11501891 — intervention group
Group type: EXPERIMENTAL
Intervention: Postfitting electroacoustic adjustments based on participant complaints/observations
Number of subjects: 0
Study 11501891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjustments made)
Number of subjects: 0
Study 9525716 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with CCNU, vincristine, and prednisone
Number of subjects: 32
Study 9525716 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with eight-drugs-in-1-day regimen
Number of subjects: 32
Study 9525716 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniospinal irradiation with a local boost to the primary tumor
Number of subjects: 32
Study 9525716 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of resection (total vs less than total)
Number of subjects: 32
Study 9525716 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual tumor size (< or = 1.5 cm2 vs > 1.5 cm2)
Number of subjects: 32
Study 8071052 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 173
Study 8071052 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 173
Study 8071052 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 173
Study 2568086 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg h.s.
Number of subjects: 375
Study 2568086 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg h.s.
Number of subjects: 375
Study 30453981 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox film-coated tablet (FCT)
Number of subjects: 173
Study 30453981 — intervention group
Group type: COMPARATOR
Intervention: Deferasirox dispersible tablets (DT)
Number of subjects: 173
Study 28669049 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic tympanoplasty
Number of subjects: 13
Study 28669049 — intervention group
Group type: COMPARATOR
Intervention: Microscopic tympanoplasty
Number of subjects: 13
Study 26092557 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel chemotherapy plus androgen deprivation therapy (ADT)
Number of subjects: 30
Study 26092557 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 30
Study 24281776 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane film dressing
Number of subjects: 38
Study 24281776 — intervention group
Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 38
Study 24281776 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dressings
Number of subjects: 38
Study 21933436 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home multicomponent cognitive behavioural programme (7 sessions: 3 home visits and 4 telephone contacts)
Number of subjects: 389
Study 21933436 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 389
Study 21933436 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home multicomponent cognitive behavioural programme
Number of subjects: 389
Study 18972062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu-(II)-orotate-dihydrate (8 mg Cu daily)
Number of subjects: 0
Study 18972062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16550600 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin 100 mg/m2 day 1 and etoposide 120 mg/m2 days 1-3 for 6 cycles)
Number of subjects: 140
Study 16550600 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 140
Study 16550600 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin and etoposide)
Number of subjects: 140
Study 12963761 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of acetaminophen, given six times daily
Number of subjects: 102
Study 12963761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 10693916 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 30
Study 10693916 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 30
Study 9282151 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Patients (SPs)
Number of subjects: 120
Study 9282151 — intervention group
Group type: COMPARATOR
Intervention: Role Playing
Number of subjects: 120
Study 7917773 — intervention group
Group type: EXPERIMENTAL
Intervention: lazabemide (100-300 mg single dose and 100-350 mg twice daily for 7 days)
Number of subjects: 75
Study 7917773 — intervention group
Group type: EXPERIMENTAL
Intervention: lazabemide
Number of subjects: 75
Study 2844876 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene E4 (LTE4) (6.1 nmol, geometric mean)
Number of subjects: 8
Study 2844876 — intervention group
Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 8
Study 2844876 — intervention group
Group type: COMPARATOR
Intervention: Diluent
Number of subjects: 8
Study 2844876 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene E4 (lower dose)
Number of subjects: 8
Study 2844876 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene E4 (higher dose)
Number of subjects: 8
Study 2844876 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene E4
Number of subjects: 8
Study 2844876 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene E4 (in normal subjects)
Number of subjects: 8
Study 29672869 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh blood stored not more than 7 days
Number of subjects: 372
Study 29672869 — intervention group
Group type: COMPARATOR
Intervention: Standard-issue blood
Number of subjects: 372
Study 28370172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care programme (part of a randomized controlled trial)
Number of subjects: 10
Study 26130002 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Job Interview Training (VR‐JIT)
Number of subjects: 39
Study 24307896 — intervention group
Group type: EXPERIMENTAL
Intervention: TOMUS (retropubic midurethral sling)
Number of subjects: 1252
Study 24307896 — intervention group
Group type: EXPERIMENTAL
Intervention: SISTEr (fascial sling)
Number of subjects: 1252
Study 24307896 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1252
Study 21214415 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture at bilateral acupoints LI‐4 and ST‐44
Number of subjects: 12
Study 21214415 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure with needle inserted bilaterally 1‐1.5 cm outside each acupoint
Number of subjects: 12
Study 21214415 — intervention group
Group type: COMPARATOR
Intervention: Control procedure with quiet rest for 20 minutes
Number of subjects: 12
Study 18492534 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy (20 to 40 mg)
Number of subjects: 144